Lee Laurie Anne 4

What Happened
Laurie Anne Lee, Chief Medical Officer of Generate Biomedicines (GENB), was granted a derivative award (option) for 42,230 shares on February 26, 2026. The filing reports an acquisition at $0.00 per share (derivative award), so no immediate cash outlay or open-market purchase/sale occurred.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (check timeliness against the two-business-day reporting rule).
• Price: reported as $0.00 (derivative award).
• Shares awarded: 42,230 (derivative/option).
• Shares owned after transaction: not specified in the provided filing extract.
• Footnote: the shares underlying this option vest in 48 equal monthly installments beginning February 19, 2026, subject to continued service.
• No indication in this filing that any shares were sold immediately (no cashless exercise or open-market sale reported).

Context
This was a time‑based equity grant (an option-like derivative) intended to vest monthly over four years — a typical retention/compensation tool for executives. Because it’s a grant rather than an open-market purchase or sale, it’s not an immediate market sentiment signal; it reflects company compensation policy and the executive’s continued-service condition.